investors.passagebio.comPassage Bio, Inc. - Investors and News - Overview
investors.passagebio.com Profile
Investors.passagebio.com is a subdomain of passagebio.com, which was created on 2017-03-20,making it 7 years ago.
Description：View investment news and earnings, press releases and upcoming events for Passage...
Discover investors.passagebio.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.passagebio.com Information
| HomePage size: 73.102 KB |
| Page Load Time: 0.355846 Seconds |
| Website IP Address: 162.159.129.11 |
investors.passagebio.com Similar Website
| Aptiv PLC - Investor Information |
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Western Midstream - Investors - Investors |
| OMNOVA Solutions - Investors - Investors |
| Investors Overview | Tesla, Inc. |
| Investors | Marathon Oil Corporation - Investors |
| Pfizer Inc. - Investors Overview |
| Axalta Coating Systems - Investors - Investors Overview |
| Business Solutions®, BIO's Cost Savings Program | BIO |
| Hyster-Yale Materials Handling, Inc., Investors - Investor Overview |
| The #1 Link In Bio Tool for Social Media - Sell on Instagram with Bio Link |
| Investors Overview | GenMark Diagnostics, Inc. |
| Connected Investors | Connect With Real Estate Investors |
| Cornerstone OnDemand, Inc. - Investors - Overview |
| Investors - Toromont Industries Ltd. - Investors |
investors.passagebio.com PopUrls
| Passage Bio, Inc. - Investors and News - Overview https://investors.passagebio.com/investors-and-news/overview/default.aspx |
| Passage Bio, Inc. - Investors and News - Stock Information https://investors.passagebio.com/investors-and-news/stock-information/default.aspx |
| Passage Bio, Inc. - Investors and News - Financials and Filings https://investors.passagebio.com/investors-and-news/financials-and-filings/default.aspx |
| Passage Bio, Inc. - Our Company - Who We Are https://investors.passagebio.com/our-company/who-we-are/default.aspx |
| Passage Bio, Inc. - Passage Bio Reports Third Quarter 2023 Financial ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2023/Passage-Bio-Reports-Third-Quarter-2023-Financial-R |
| Passage Bio, Inc. - Investors and News - News https://investors.passagebio.com/investors-and-news/press-releases-and-statements/default.aspx |
| Press Releases and Statements - Passage BIO, Inc. https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2023/Passage-Bio-Reports-Fourth-Quarter-and-Full-Year-2 |
| Passage Bio, Inc. - Passage Bio Reports Second Quarter 2022 Financial ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Reports-Second-Quarter-2022-Financial- |
| Passage Bio, Inc. - Passage Bio Reports Third Quarter 2022 Financial ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Reports-Third-Quarter-2022-Financial-R |
| Passage Bio, Inc. - Passage Bio Reports Fourth Quarter and Full-Year ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Reports-Fourth-Quarter-and-Full-Year-2 |
| Passage Bio, Inc. - FDA Clears IND Application for Passage Bio's Gene ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/FDA-Clears-IND-Application-for-Passage-Bios-Gene-T |
| Passage Bio, Inc. - Investors and News - Events and Presentations https://investors.passagebio.com/investors-and-news/events-and-presentations/default.aspx |
| Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial ... https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2023/Passage-Bio-to-Report-Fourth-Quarter-and-Full-Year |
| Press Releases and Statements - Passage BIO, Inc. https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2021/Passage-Bio-Announces-Pipeline-Expansion-and-Clini |
| Press Releases and Statements - Passage BIO, Inc. https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Announces-Positive-Interim-Clinical-Da |
investors.passagebio.com Httpheader
| Date: Mon, 13 May 2024 17:15:09 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 883449f6292b323e-LAX |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-Frame-Options: SAMEORIGIN |
| X-XSS-Protection: 1; mode=block |
| Server: cloudflare |
investors.passagebio.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1" name="viewport"/ |
| content="default-src 'self' https: http: 'unsafe-inline' 'unsafe-eval' *.q4inc.com; script-src 'self' *.cloudfront.net *.pusherapp.com *.newrelic.com *.nr-data.net *.twitter.com *.platform.twitter.com *.cdn.syndication.twimg.com *.twimg.com *.bugherd.com *.q4cdn.com *.q4web.com *.amazonaws.com *.highcharts.com *.googletagmanager.com *.googleadservices.com *.google-analytics.com *.google.com *.gstatic.com *.q4app.com *.pendo.io *.ads-twitter.com *.licdn.com *.facebook.net 'unsafe-inline' 'unsafe-eval' *.q4inc.com" http-equiv="Content-Security-Policy"/ |
| content="9qpNu15GYXo5NF5CjUdVU9QSiK4GckrK-y5oB8QSlkE" name="google-site-verification"/ |
| content="https://s27.q4cdn.com/477254652/files/design/PassageBioSocialImage.png" property="og:image"/ |
| content="https://s27.q4cdn.com/477254652/files/design/PassageBioSocialImage.png" name="twitter:image"/ |
| content="Investor Overview | Passage Bio" name="title"/ |
| content="View investment news and earnings, press releases and upcoming events for Passage Bio." name="description"/ |
| content="Investor Overview | Passage Bio" property="og:title"/ |
| content="View investment news and earnings, press releases, and upcoming events for Passage Bio." property="og:description"/ |
| content="https://www.passagebio.com/investors-and-news/overview/" property="og:url"/ |
| content="https://www.passagebio.com/investors-and-news/overview/default.aspx" name="url"/ |
investors.passagebio.com Html To Plain Text
Our Company Who We Are Our Team Our Science Our Approach Role of Progranulin Manufacturing Pipeline Overview Frontotemporal Dementia GM1 Gangliosidosis Patients and Caregivers Our Commitment Compassionate Use Statement Community Resources Investors and News Overview News Events and Presentations Financials and Filings Stock Information Investor FAQs Resources Corporate Governance Inquiries and Alerts Careers Contact Toggle Site Search Search query Search query Our Company Who We Are Our Team Our Science Our Approach Role of Progranulin Manufacturing Pipeline Overview Frontotemporal Dementia GM1 Gangliosidosis Patients and Caregivers Our Commitment Compassionate Use Statement Community Resources Investors and News Overview News Events and Presentations Financials and Filings Stock Information Investor FAQs Resources Corporate Governance Inquiries and Alerts Careers Contact in tangible. The power of gene therapy can change more than words. It can transform potential. Overview Passage Bio is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. Our team’s unwavering commitment to excellence is the driving force behind our mission to protect patients and their families against loss in neurodegenerative conditions. Our approach involves developing cutting-edge, one-time treatments that are underpinned by rigorous scientific research and state-of-the-art CMC analytics. Our team’s unwavering commitment to excellence is the driving force behind our mission to protect patients and their families against loss in neurodegenerative conditions./pNotice of Pendency and Settlement of Stockholder Action Download PDF (opens in new window)Press Releases Read More Read the latest news about Passage Bio CONTACT US | PRIVACY POLICY | SITE MAP | UnsubscribePRIVACY POLICY | SITE MAP The information on this website is intended for use by US residents only. © Passage Bio. All Rights Reserved. FOLLOW US Facebook (Opens in new window) Twitter (Opens in new window) Linkedin (Opens in new window) The information on this website is intended for use by US residents only. © Passage Bio. All Rights Reserved. Powered By Q4 Inc. 5.122.0.3 (opens in new...
investors.passagebio.com Whois
Domain Name: PASSAGEBIO.COM Registry Domain ID: 2106481126_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-10-16T11:32:50Z Creation Date: 2017-03-20T15:43:02Z Registry Expiry Date: 2027-03-20T15:43:02Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS63.DOMAINCONTROL.COM Name Server: NS64.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T17:55:12Z <<<